ONCO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 16:00):

Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide...

Stats
Today's Volume	531 091
Average Volume	574 904
Market Cap	2.76M
Next earnings date	( $-0.210 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00200 (1.62%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-16	Singh Ajit	Buy	3 125	Common Stock
2024-02-08	Singh Ajit	Buy	0
2024-02-06	Meier Thomas	Buy	0
2003-12-05	Liberty Media Corp /de/	Sell	22 897 677	Common Stock

INSIDER POWER
100.00
Last 2 transactions
Buy: 3 125 \| Sell: 22 897 677

Volume Correlation

Long: -0.05 (neutral)

Short: -0.63 (weak negative)

Signal:(54.155) Neutral

Onconetix, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Onconetix, Inc. Correlation - Currency/Commodity

-0.40
( neutral )

0.54
( weak )

0.00
( neutral )

-0.82
( strong negative )

Onconetix, Inc. Financials

Annual	2023
Revenue:	$58 465.00
Gross Profit:	$-1.14M (-1 950.17 %)
EPS:	$-2.19

FY	2023
Revenue:	$58 465.00
Gross Profit:	$-1.14M (-1 950.17 %)
EPS:	$-2.19

Financial Reports:

No articles found.

Onconetix, Inc.

Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.